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Abstract: 
Eosinophilic gastrointestinal disorders are a set of conditions with a wide range of clinical 
manifestations and treatment modalities. The disorders are suspected to result from an abnormal 
inflammatory response to allergen(s), and individuals may develop a relapsing or chronic 
disease, if the allergen is not eliminated. Mechanisms of disease pathogenesis, including the 
humoral immune response, need to be fully elucidated. A variety of therapies are used, though 
there is a lack of well-defined randomized, prospective studies. Other therapeutic options are 
needed as the current treatments have potential concerns; elimination diets may impair a child’s 
quality of life, and corticosteroids have adverse risks with long-term use. We review what is 
known about non-esophageal eosinophilic gastrointestinal disorders, and discuss research 
investigations which need to be conducted to facilitate diagnosis and enhance treatment methods.             
What is Known: 
• Eosinophilic gastrointestinal disorders can be difficult to diagnose due to variability in
clinical presentation and a low prevalence, particularly in children.
• Dietary elimination of food allergens and treatment with corticosteroids provide clinical
and histological improvement.
What is New: 
• Mouse models have demonstrated key aspects to the pathophysiology of eosinophilic
gastrointestinal disease.
• Translational studies are needed to identify new therapeutic targets and clinical
applicability in humans.
• Large, longitudinal clinical investigations, including multi-center consortium, aim to
define the natural history of these rare disorders and develop standardized diagnostic and
management guidelines.
Introduction 
Eosinophilic gastrointestinal disorders (EGIDs) are conditions with an elevated number 
of eosinophils in any segment of the GI tract. Eosinophilic esophagitis (EoE), the most described 
and encountered of EGIDs, is a chronic, immune-mediated disease which causes esophageal 
dysfunction and histologically demonstrates >15 eosinophils per high-power field (eos/HPF) on 
esophageal biopsies. About a third of patients with esophageal eosinophilia will respond to high-
dose proton pump inhibitor (PPI) and are considered to have proton pump inhibitor-responsive 
esophageal eosinophilia (PPI-REE) [1]; non-responders require dedicated treatment for EoE.  
Non-esophageal EGIDs (neEGIDs) present with diverse symptomology and increased 
intestinal eosinophilia without a known secondary etiology. Eosinophilic gastritis (EG) causes 
upper GI symptoms, including abdominal pain, vomiting, and failure to gain weight. 
Eosinophilic gastroenteritis (EGE) typically involves the stomach and small bowel to produce a 
multitude of upper and lower intestinal symptoms. Eosinophils may be elevated in segments or 
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throughout the colon in eosinophilic colitis (EC). In addition, eosinophils can be present at 
varying depths of the intestinal wall, from the mucosa to the serosa. Due to the wide-spectrum of 
symptoms, neEGIDs have a broad differential diagnosis (Table 1).  
While there remains much to be learned about the pathophysiology and management, we 
aim to increase clinicians’ awareness of neEGIDs in order to make a timely diagnosis, provide 
appropriate long-term care, and foster research to advance the field.      
 
Prevalence 
EG, EGE, and EC have a reported prevalence of 6.3, 8.4, and 3.3/100,000 people, 
respectively. In children, the prevalence is 4.4, 10.7, and 4.3/100,000, respectively [2]. In 
comparison, EoE has a prevalence of 1/2,000 children [3]. The prevalence of EG increases with 
age, being highest in the 7th decade of life, while the prevalence of EGE is highest in children 
under age five years. The prevalence of EC does not significantly differ by age (Table 1) [2].   
There is a baseline female predominance in all neEGIDs but particularly in EG with 
7.9/100,000 cases in females versus 5.4/100,000 cases in males [2]. This female preponderance 
is in stark contrast to EoE where the gender ratios are reversed. 
neEGIDs may coexist with other allergic and/or atopic conditions, food sensitivities, 
and/or EoE [5]. The reported co-incidence of EoE with EG, EGE, and EC is 10.6%, 12.0%, and 
10.9%, respectively. About a third of neEGID patients have concomitant atopy with similar 
incidences in children and adults [2].  
 
Pathophysiology 
 
neEGID has been hypothesized to involve IgE and non-IgE-mediated immune 
mechanisms. Patients are suspected to have an abnormal response to food or environmental 
allergens, which may differ based on demographics, geographic location, and/or season [4].  
Eotaxin, a selective chemokine regulating eosinophil migration, binds to the eosinophilic 
chemokine receptor CCR3, which leads to further upregulation of cytokines, including 
interleukins (IL) IL-3, IL-5, and IL-13 [5]. Mice exposed to oral antigens develop eosinophilic 
inflammation of the esophagus, stomach, and small intestine through eotaxin-mediated signaling 
(6).  
Torrente, et al. [6], found that patients with EC had a higher density of CD3+ T cells, 
eotaxin-2+ intraepithelial lymphocytes, and IgE+ cells in the lamina propria than patients with 
inflammatory bowel disease (IBD). There were a higher number of degranulating eosinophils 
and mast cells along with elevated tryptase and IgE concentrations near mucosal enteric nerves 
in patients with EC, but not those with IBD or healthy controls. It is thought that these changes 
lead to mucosal permeability, dysmotility, and visceral hyperalgesia in EC.         
STAT6-mediated immune mechanisms are involved in food-induced intestinal 
inflammation in mice [7]. STAT6 signaling leads to the production of IL-4 and IL-13 by Th-2 
cells, and unlike control mice, STAT-/- mice do not develop diarrhea, exhibit intestinal 
eosinophilia, or produce Th-2 cytokines or IgE antibodies when stimulated with oral ovalbumin.  
The role of mast cell release of leukotrienes has been debated in EoE and requires further 
investigation in neEGIDs too [8]. Allergens bind to the IgE receptor on mast cells and basophils 
leading to cell activation and release of inflammatory mediators, including IL-13 which is 
involved with eosinophil recruitment [9, 10]. Mast cells may also increase intestinal 
permeability; patients with EGE and protein-losing enteropathy had higher numbers of mucosal 
mast cells than those without [11]. Future investigations will determine if these molecular 
markers can be therapeutic targets.    
 
Clinical Presentation 
 
Patients with neEGID generally demonstrate symptoms based on the location and the 
depth of tissue eosinophilia (Table 1). EG may present with epigastric pain, vomiting, or weight 
loss [2]. Patients with EGE may have upper and lower GI symptoms, including abdominal pain, 
vomiting, hematemesis, or diarrhea. EC may manifest as abdominal pain, diarrhea and/or 
constipation, or lower GI bleeding. Mucosal eosinophilia may cause protein-losing enteropathy 
leading to hypoalbuminemia, whereas eosinophilic inflammation of the muscularis mucosa may 
lead to impaired motility or anatomical obstruction. Eosinophilic infiltration of the serosa may 
result in non-specific bloating or more worrisome ascites (Table 1) [4, 12, 13]. Approximately 
60-70% of patients with EGE have peripheral eosinophilia which differs from the wide range in 
EoE of 20-100% of children; some patients may have elevated serum IgE levels [5, 8, 14].  
 
Endoscopic and Histologic Features 
 
As with EoE, the diagnosis of neEGID requires endoscopic evaluation and histological 
examination of the GI tract. Endoscopy may be visually normal or demonstrate mucosal 
erythema, edema, ulcerations, nodularity, or polypoid lesions. Histologically, there is 
eosinophilia along with degranulated eosinophils, cryptitis, crypt abscesses, and/or chronic 
architectural changes. Infiltration of other inflammatory cells, such as neutrophils or plasma 
cells, may be encountered but is generally not proportional to the density of eosinophilic 
inflammation [2]. Eosinophils may be located in lamina propria, muscularis mucosa, and/or 
submucosa [4]. However, endoscopically-obtained tissue biopsies contain only mucosa/lamina 
propria, and the diagnosis might be missed if only deeper tissue levels contain eosinophilia.  
 
Diagnosis 
 
Diagnosing neEGIDs can be challenging as the diseases have a variable clinical 
presentation, may be segmental in location, and be outside the reach of endoscopically-obtained 
biopsies. Diagnostic criteria have not been conclusively established, and diagnosis is often based 
on eosinophil load on biopsies in the appropriate clinical setting. Physiological eosinophil load in 
different parts of the GI tract generally increases in a descending manner, save the colon where it 
is higher in the right colon compared to the distal colon (Figure 1) [4, 15, 16]. Additional studies 
have evaluated the number of tissue eosinophils based on age, sex, and history of atopic disease, 
but no significant correlations were found [15, 17].  
The histologic criteria for neEGIDs include a significant increase in intestinal eosinophil 
load; EG exhibits ≥30 eos/HPF in 5 HPFs or ≥70 eosinophils ≥3 HPFs [18, 19]. EGE 
demonstrates ≥52 eos/HPF in the duodenum and ≥56 eos/HPF in the ileum. EC is considered if 
there are greater than twice the normal number of eosinophils, with ≥100 eos/HPF in the right 
colon, ≥84 eos/HPF in the transverse and descending colon, and ≥64 eos/HPF in the 
rectosigmoid colon. Biopsies should be evaluated for cellular degranulation, crypt architectural 
distortion, and eosinophilic cryptitis [20]. IBD may be the most difficult to differentiate from EC 
as there is eosinophilia in the lamina propria, but IBD also has acute and chronic inflammatory 
cells [21]. EC typically does not demonstrate acute inflammation, and its diagnosis is often made 
after excluding other etiologies. Thus, the diagnosis of neEGIDs, as for IBD, should take into 
consideration clinical symptoms, endoscopic findings, and pathology.  
 
Management 
 
The low prevalence of neEGIDs, the limited number of placebo-controlled clinical trials, 
and gaps in our understanding of the natural history lead to empiric therapeutic and management 
decisions based on experience rather than evidenced-based protocols. As with EoE, it is unclear 
if treatment end-points in neEGIDs should be solely based on histological criteria, i.e. return of 
eosinophil load to physiological numbers or a composite of clinical, endoscopic, and histologic 
criteria [22].  
Dietary restriction or corticosteroids are common treatment methods, though other 
agents, such as biologics, are being investigated. Dietary therapy is often recommended due to 
the lower risk of adverse effects than corticosteroids and a high rate of efficacy [19, 22]. In a 
systemic review by Lucendo, et al. [22], 86 patients with EG and EC were given an elemental or 
hydrolyzed protein formula or advised to follow the 6- or 7-food elimination diet. 68 (79%) 
patients demonstrated clinical improvement, and 16/20 (80%) patients who had follow-up 
biopsies had histological improvement or remission. Remission was defined as <20 eos/HPF in 
the stomach, small intestine, or colon [23]. Ko, et al. [19] evaluated elemental formula or food 
elimination diet in 17 patients with EG. 14/17 (82%) patients had symptom resolution and 11/14 
(79%) who had post-therapy biopsies had histological remission with <10 eos/HPF.  
Topical or systemic corticosteroids have been used to induce remission, but patients may 
develop resistance to corticosteroids or relapse upon discontinuation as reported in 42% of a 
cohort of EGE patients [5]. Budesonide can be given for EG and EGE, and the controlled ileal-
release capsule can be used in EC. Swallowed fluticasone may benefit patients with concomitant 
EoE and EG, but the delivery may not treat EGE [23]. Patients may require low-dose 
maintenance therapy, particularly if they relapse upon discontinuation of corticosteroids [12].  
Various other medications have been studied, including montelukast, a leukotriene 
receptor antagonist, and PPIs. Case reports demonstrate inconsistency of montelukast in 
maintaining remission in EGE, even after induction therapy with corticosteroids [5, 24, 25]. PPIs 
have exhibited variable and limited results in EG and EGE, and more studies are needed. In case 
reports, patients who were unresponsive to a PPI required treatment with corticosteroids or 
dietary elimination [26-28].  
Biologic agents have produced mixed results with EoE, thereby tempering the enthusiasm 
for neEGIDs [29-31]. Reslizumab and mepolizumab, monoclonal antibodies to IL-5, 
demonstrated sub-optimal attainment of remission in EoE. QAX576, a monoclonal antibody to 
IL-13, has been studied in EoE but not neEGIDs. Omalizumab, a monoclonal antibody to IgE, 
has been investigated in EoE and EGE, but did not demonstrate consistent improvement in 
symptoms or endoscopic and histologic findings [9, 32, 33]. Biologic agents need further study 
in neEGIDs and may need to be used with other therapeutic modalities to target multiple 
pathways that result in intestinal eosinophilia. 
Adherence to treatment is crucial in order for patients to maintain remission. In a study 
by Hommel, et al. [34], 30% of patients with EoE or EGE demonstrated non-adherence to 
dietary and medical therapy. Compliance must be emphasized in order to mitigate relapse and 
long-term complications.  
Another unmet need is guidance on endoscopic and histological evaluation and 
monitoring of patients with neEGIDs. A high index of suspicion should be maintained not only 
for initial diagnosis, but during follow-up as eosinophilia may manifest in another segment(s) of 
the GI tract which was/were previously unaffected [35]. Prospective studies are needed to 
determine the appropriate timing of follow-up endoscopy and the location and number of 
biopsies to obtain.      
The NIH-funded Consortium for Eosinophilic Gastrointestinal Disease Research 
(CEGIR) is conducting multicenter, longitudinal studies to evaluate clinical outcomes, histology, 
and molecular markers associated with EG, EGE, and EC. These studies will allow for the 
creation of standardized treatment guidelines. In addition, CEGIR has a portal where patients can 
register and input their information, https://www.rarediseasesnetwork.org/cms/cegir/Get-
Involved/Contact-Registry [37].   
 
Conclusions and Future Directions 
 
It is important for gastroenterologists to consider neEGIDs in the appropriate clinical 
setting. Dietary modifications and corticosteroids are the most commonly used treatment options, 
though further studies in these and other therapies are needed. Improved understanding of the 
pathophysiology and natural history of neEGIDs will help drive the therapeutic field, and several 
drugs, including small molecules and biologics, are currently in development to target biological 
markers in eosinophilic diseases [36]. Long-term follow-up including timing of endoscopic 
evaluation, location and number of biopsies for histological evaluation, and duration of therapy 
are unmet needs. Ongoing individual efforts and multi-center consortia, such as CEGIR, provide 
platforms for us and patients to collectively move the field forward. 
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Tables and Figures:  
 
Table 1: Clinical presentation of non-esophageal eosinophilic gastrointestinal disease 
 
Figure 1: Expected physiological numbers of eosinophils in the intestinal tract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Clinical presentation of non-esophageal eosinophilic gastrointestinal disease 
 
 Eosinophilic Gastritis Eosinophilic 
Gastroenteritis 
Eosinophilic Colitis 
Age of Prevalence increases with age, 7th 
decade 
less than 5 years similar for all ages 
Gender  Female > male Female  > male Female  > male 
Symptoms epigastric pain, 
dyspepsia, vomiting, 
early satiety, oral 
aversion, failure to 
gain weight 
abdominal pain, 
dyspepsia, vomiting, 
hematemesis, 
bloating, diarrhea 
abdominal pain, diarrhea 
and/or constipation, lower 
gastrointestinal bleeding, 
tenesmus 
Mucosal eosinophilia malabsorption weight 
loss, ulcerations,  
malabsorption, 
anemia, protein-
losing enteropathy  
protein-losing enteropathy, 
bleeding  
Muscularis mucosa 
eosinophilia 
gastric outlet 
obstruction 
intussusception, 
dysmotility 
intussusception, 
dysmotility 
Serosal eosinophilia bloating bloating, ascites ascites, edema 
Differential 
Diagnosis 
peptic ulcer disease, infection, drug injury, 
toxins, neoplasm, vasculitis, 
hypereosinophilic syndrome, Langerhan 
cell histiocytosis 
 food protein-induced 
enterocolitis, allergic 
proctocolitis, inflammatory 
bowel disease 
 
 
Figure 1: Expected physiological numbers of eosinophils in the intestinal tract 
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